Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2010 January 4.
Published in final edited form as:
PMCID: PMC2801157

Go Red for Women: Thrombosis and Anti-Thrombotic Therapy in Women


Sex-based differences in the prevalence and presentation of arterial and venous thrombosis exist, and emerging data indicates that men and women do not accrue equal benefit from anti-thrombotic therapy. Sex hormones alter procoagulant protein expression and the function of blood and vascular cells. Sex-based differences in platelet function have been reported, and in animal models, sex-based differences in thrombosis have been noted. Here we review plausible mechanisms that may explain how sex functions as a modifier of thrombosis and summarize clinical data on the interaction between sex and response to anti-thrombotic therapy.

Thrombosis is a leading cause of death world-wide and complicates atherosclerotic disease, heart failure, cancer, surgery and pregnancy. Antithrombotic therapy is the cornerstone in the prevention and treatment of arterial thrombosis (e.g. myocardial infarction and stroke), venous thromboembolic disorders, and the complications of atrial fibrillation. Sex-based differences in the pathophysiology and treatment of thrombosis have been examined in a growing body of literature. Although women tend to be underrepresented in randomized clinical trials of anti-thrombotic therapy, most analysis indicate that men and women accrue equal therapeutic benefit in a variety of clinical settings. However, emerging data suggests that women may respond differently to some anti-platelet agents. We will review the data in support of sex-based differences in thrombosis and anti-thrombotic therapy and present potential biologic explanations for the observed differences.

Biologic Basis for Sex Differences in Predisposition to Thrombosis

Important differences in the age of presentation of cardiovascular disease exist between men and women, which may, in part, reflect underlying differences in propensity to thrombosis. Sex hormones have complicated effects on the vessel wall, coagulation proteins, and platelets that may alter thrombosis. Cylic patterns in coagulation proteins1 and circulating microparticle2 levels corresponding to menstrual cycle patterns have been observed in women. Liver secretion of coagulation factors is influenced by sex and growth hormones3. Continuous estrogen decreases plasma levels of fibrinogen, antithrombin, protein S, and plasminogen activator inhibitor4. However, while estrogen tends to lower plasma fibrinogen, women have modestly higher fibrinogen levels than their male counterparts. In the Fibrinogen Studies Collaboration, a meta-analysis of findings from 31 studies involving 154,211 apparently healthy adults, fibrinogen levels in women were on average 0.12 g/L higher than in men5.

Animal models have been employed to provide mechanistic insight into pathophysiology of sex-based differences in thrombosis and to avoid the confounding influences that can affect human phenotypes. While many such differences have been observed in animal models, the findings vary from species and strain, and thus extrapolating the findings from animal models to humans must be done with caution. An examination of 42 strains of mice revealed mean prothrombin times (in seconds) of 10.5 ± 0.662 in female mice and 10.4 ± 0.55 in male mice, with several strains (DBA/2J, C3H/HeJ, and SEA/GnJ) showing evidence for lower times in females and several (SWR/J and NZW/LacZ) in which times tended to be lower in males6. A similar profile of fibrinogen levels demonstrated lower mean levels in female mice (190 ± 31.3 mg/dl) than in males (235 ± 36.5 mg/dl)6. In a mouse pulmonary embolism model, male mice were more susceptible to thrombosis and had faster clotting times ex vivo, apparently related to differences in the patterns of growth hormone secretion in males (pulsatile) and females (sustained) which in turn influence the production of proteins that regulate coagulation and thrombosis3.

Sex differences in platelet function

Substantial evidence points to sex differences in platelet function in animals and humans. In the case of rats, platelets isolated from male rats display greater maximal aggregation in vitro than platelets isolated from female rats7, 8 The thromboxane A2-mimetic U46619 elicits greater thrombus burden and more death in male rats 9. Castration reduces platelet aggregation in male rats10. In contrast, platelets isolated from female mice bind more fibrinogen and have a greater maximal extent of aggregation in response to weak and low-dose agonists than do platelets isolated from male mice 11. Additionally, treatment of ovariectomized mice with estrogen alters ex vivo platelet reactivity 12.

Many but not all, studies of human platelet function have observed heightened responsiveness of platelets isolated from women. Although human platelets isolated from women may have less integrin αIIbβ3 [glycoprotein (GP) IIb/IIIa], they bind more fibrinogen in response to ADP and thrombin-receptor stimulation and form larger aggregates 13-16. The nature of the agonist may be important in sex difference of human platelet function, because male human platelets reportedly have greater responses to activation of α2-adrenergic and serotonin signaling pathways.

The differences in ex vivo platelet function observed in men and women could be the result of direct platelet effects of estrogens, progesterone and/or androgens or could be an indirect effect through effects of sex hormones on the vasculature. Both megakaryocytes and platelets express the estrogen receptor β and the androgen receptor 17. A number of studies support a direct effect of estrogen on platelet function Exposure of platelets in vitro to estrogen inhibits ADP, epinephrine, and shear-induced platelet aggregation 17-19. Differences in ex vivo platelet function during the follicular and luteal phases have been observed and may relate to alterations in plasma progesterone levels 20. Finally, in mice, estrogens act through the estrogen receptor α in the vessel wall to upregulate production of prostaglandin I2, lower platelet activation and down regulate thromboxane synthesis21. Estrogen-mediated platelet inhibition via prostaglandins in vivo could translate into heightened activation of isolated female platelets because of the transient nature of the platelet inhibitory effects of prostaglandins.

The androgen receptor may also regulate megakaryocyte biology and platelet production. Androgen therapy improves platelet count in myleodysplastic syndrome. Castration of mice reduces platelet count, which is restored by administration of testosterone. Indeed, a profile of platelet counts across 43 strains of mice indicated that, with a few exceptions, male mice of most strains had similar or higher platelet counts than their female counterparts6.

Sex Differences in Effects of Anti-Platelet Therapy as Measured by Ex Vivo Assays

Several studies have demonstrated a higher prevalence of the phenomena of “aspirin resistance”, defined as the failure of aspirin to inhibit platelet function as measured by a variety of assays, among females. For example, when platelet function is assayed ex vivo by light transmission aggregometry or in the PFA-100 assay, the results are higher for women than men consuming aspirin 22, 23. To determine whether aspirin fails to suppress platelet function in women, Becker et al. 13 studied platelet function in samples from 571 men and 771 women before and after aspirin use. In keeping with other reports, they found platelets from women were more responsive in 10 of 12 baseline platelet function tests. After low- dose aspirin therapy (81 mg) for 14 days, ex vivo platelet function declined to a similar or greater extent in women. However, because of the heightened baseline reactivity, the absolute extent of platelet aggregation was greater in women than in men after 14 days of low-dose aspirin. In a smaller study of 106 healthy individuals, women also had higher residual ex vivo platelet aggregation after 14 days of high-dose aspirin (325 mg) then did men 24. These finding may help to explain the higher prevalence of “aspirin resistance” in women – because at baseline women have greater platelet function in ex vivo assays, their values tend to remain higher after aspirin therapy.

Anti-Thrombotic Therapy in Arterial Thrombosis (Myocardial Infarction and Stroke)

Platelets are essential to atherothrombosis and, therefore, anti-platelet therapy is pivotal in preventing and treating acute myocardial infarct (MI) and ischemic stroke (cerebral vascular accident; CVA). In the setting of acute MI, stroke or transient ischemic attack, and in other “high risk” populations, namely those with unstable angina and prior MI, the benefits of aspirin in preventing recurrent ischemic events are similar in men and women. The Second International Study of Infarct Survival (ISIS-2)25, the first large, randomized clinical trial to evaluate the benefits of aspirin in the setting of acute MI, demonstrated that aspirin reduced the risk of vascular death at five weeks in both women [relative risk (RR) 0.84] and men (0.78)25. In the setting of acute CVA, aspirin also lowers the risk of recurrent ischemic strokes to a similar degree in women and men 26, 27. Among “high-risk” patients, women receive the same benefit from aspirin therapy as do men, including a 34% decrease in nonfatal MI, a 25% decrease in nonfatal stroke, and a 15% decrease in vascular death 28.

Unlike studies in high risk patients, studies of aspirin for primary prevention of cardiovascular disease in healthy individuals have revealed sex-based differences in responses to therapy. The Nurses' Health Study, a nonrandomized prospective cohort study that followed more than 85,000 females in the United States, found that women taking one to six aspirin per week had a lower risk of MI within the first six years of follow-up (RR 0.75) than women who did not take aspirin 29. At 24 years of follow-up, a significantly lower risk of death from all causes was observed among women who used aspirin regularly versus those who never used aspirin (RR 0.75) 30. The greatest risk reduction was in death from cardiovascular disease and stroke (RR 0.62 each). A linear relationship was seen between increasing duration of aspirin use and decreasing mortality. The observations from the Nurses' Health Study spurred three large randomized trials to evaluate the role of aspirin as primary prevention in women (summarized in Table 1). In the Hypertension Optimal Treatment (HOT) trial, men and women with hypertension were randomized to aspirin or placebo. Aspirin significantly lowered the risk of MI in men (RR 0.58), with no significant effect seen in women 31. There was no reduction in stroke risk seen in either men or women. The Primary Prevention Project randomized over 4400 people to aspirin or placebo with or without vitamin E 32. A nonsignificant increased risk of MI in women [Odds Ratio (OR) 1.37] and a decreased risk of MI in men (OR 0.50) was observed in this trial. For stroke, there was a trend toward a decreased risk in women (OR 0.68) but not in men (OR 1.16) 33. In the largest study of aspirin in primary prevention, the Women's Health Study randomized over 39,000 healthy women to aspirin or placebo. Aspirin had no significant effect of the risk of MI (RR 1.02) in the overall study population, but decreased the risk of MI in women over the age of 65 (RR 0.66) 34. Aspirin significantly lowered the risk of ischemic stroke (RR 0.76) and nonsignificantly increased the risk of hemorrhagic stroke (RR 1.24). It is important to note that the dose of aspirin used in the Women's Health Study was low (100 mg every other day) and that higher doses might be required for adequate platelet inhibition. In a meta-analysis of primary prevention trials involving more than 95,000 patients, aspirin had no effect on risk of myocardial infarction (OR 1.01) or cardiovascular death (OR 0.90) in women33, but did lower the risk of ischemic stroke (OR 0.76). In men, aspirin therapy reduced the risk of MI (OR 0.68) without any effects on the risk of ischemic stroke (OR 1.00) or cardiovascular death (OR 0.99). There was an increased risk of hemorrhagic stroke noted in men taking aspirin (OR 1.69). The risk of bleeding, mostly gastrointestinal, was increased with chronic aspirin use to a similar degree in women (OR 1.68) and men (OR 1.72).

Table 1
Clinical Trials Examining Aspirin as Primary Preventive Therapy in Women

Few studies have examined responses of men and women to clopidogrel, a prodrug that is metabolized to a P2Y12 purinergic receptor antagonist that inhibits platelet activation by ADP. Plasma levels of the active metabolite of clopidogrel are similar in men and women 35. The available evidence indicates that clopidogrel is equally efficacious in women and men. In the Clopidogrel for the Reduction of Events During Observation (CREDO) trial, the benefit of a loading dose of clopidogrel prior to percutaneous revascularization was similar in men and women 36.

Inhibition of the major platelet integrin αIIbβ3 (GPIIb/IIIa), which is the final common step in platelet aggregation, reduces the risk of ischemic complications in the setting of percutaneous coronary interventions. In a meta-analysis of over 31,000 patients presenting with acute coronary syndromes, a significant interaction between sex and treatment was observed, with rates of death and MI lower in men (OR 0.81) but not women (OR 1.15) receiving GPIIb/IIIa receptor blockers. The sex and treatment interactions held after adjustment for differences in baseline characteristics 37. In a subset of patients for whom values of the myocardial necrosis biomarker troponin were available, GPIIb/IIIa inhibitors reduced the rates of MI and death in both troponin-positive men and women but had no benefit in troponin-negative patients of either sex. Sex differences in platelet response to GPIIb/IIIa inhibition have not been observed in vitro38, 39, thus the clinical observations may reflect fundamental differences in the presentation of atherothrombosis in men and women.

Atrial Fibrillation, Stroke, and Anti-Thrombotic Therapy

Atrial fibrillation is the most common arrhythmia encountered in clinical practice and is a major risk factor for stroke 40. Women appear to be at higher risk for suffering a stroke in the setting of atrial fibrillation than men 41-45, and women over the age of 75 years are at the highest risk of stroke 46. In keeping with these observations, atrial fibrillation is more frequently noted in women presenting with a stroke than men 47, 48.

In comparison to placebo, aspirin therapy reduces the incidence of stroke by 19% to 25% with equal efficacy in men and women 47, 49. Warfarin therapy reduces the incidence of stroke by 64% in patients with atrial fibrillation compared to placebo 49. Warfarin therapy is at least equally effective in lowering the risk of thromboembolism in men and women, with some studies showing more benefit in women 41, 50. Importantly, several recent trials have disclosed similar rates of major bleeding in women and men with warfarin therapy and in particular, there is no increased risk of intracranial bleeding 41, 44, 51. Investigational oral thrombin inhibitors are being studied in atrial fibrillation. In a randomized trial comparing the oral thrombin inhibitor ximelagatran to coumadin, the use of the oral thrombin inhibitor in women was associated with higher stroke rates whereas there were no difference in stroke rates by treatment in men51.

Venous Thromboembolic Disease

Venous thromboembolism (VTE) occurs in 1 out of every 1000 persons per year 52, with the incidence rising exponentially with age 53. Overall, the incidence of VTE appears to be the same in men and women. However, the age distribution varies by sex with slightly higher numbers of younger women and older men suffering VTE 54. The higher rates of VTE in younger women have been attributed largely to hormonal influences, namely oral contraceptive (OCP) use, pregnancy and the puerperium. The absolute risk of VTE with OCP use is low, with reported rates of 1 in 2000 to 3500 55. However, this represents a 2-8 fold increase in risk. Use of combined hormone replacement therapy similarly increases the risk of VTE 2-4 times 56-58. Women have a lower risk of recurrent VTE after discontinuation of anticoagulation therapy as compared to men 59-64. The lower risk of recurrence may be explained in part by a significantly lower risk of recurrence in hormonally (OCP, hormone replacement, or pregnancy) related VTE (5%) vs. non-hormonally related VTE (15%)59, although a prothrombotic tendency in men as has been observed in animal models 3, cannot be excluded.

Pregnancy is associated with a 5 – 10 fold increase in the risk of thrombosis. In fact, pulmonary embolism is the most common cause of maternal death post delivery in developed countries 54. The risk of VTE increases with advanced maternal age, smoking, obesity, lupus, pre existing heart disease, sickle cell disease and preeclampsia, and births requiring transfusions. Of interest in discussions of thrombophilia and pregnancy is the role thrombosis plays in conditions mediated by placental insuffiency such as recurrent pregnancy loss and preeclampsia 55.


In summary, sex hormones alter procoagulant protein levels, platelet function, and the vessel wall in a manner that may translate into sex-based differences in thrombosis. Moreover, the male pattern of growth hormone secretion may regulate coagulation and thrombosis. The differences in platelet and coagulation function may, at least in part, explain the clinical observations that women are more likely to be aspirin-resistant, to accrue distinct benefits from aspirin therapy as primary prevention, and to present with different patterns of VTE and stroke in the setting of atrial fibrillation. Additionally, alterations in vessel wall biology between men and women may contribute to differences in thrombosis patterns and responses to anti-thrombotic therapy. In particular, the ability of aspirin therapy as primary prevention to lower MI in men and stroke in women and the differences in treatment benefit of GPIIb/IIIa inhibitors in women with acute coronary syndromes may reflect differences in the nature, burden, and presentation of atherosclerotic disease between women and men. All anti-thrombotic therapy is associated with an increased risk of bleeding. Bleeding complications are often higher in women, in part due to their smaller size and often older age at presentation than men. However, sex-based differences in vessel or blood function may exist that contribute to increased bleeding rates in women. Clearly additional studies are needed to define the mechanisms that control sex-based differences in thrombosis at the molecular, cellular and whole organismal level. Moreover, clinical trials should rigorously examine the benefits and risks of anti-thrombotic therapy by sex, to ensure efficacy and safety in women and men.


This work was supported in part by grant support from the N.I.H. (HL078663 and HL080166)to S.S.S.

Reference List

1. Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Thromb Haemost. 1999;82:1456–61. [PubMed]
2. Toth B, Nikolajek K, Rank A, Nieuwland R, Lohse P, Pihusch V, Friese K, Thaler CJ. Gender-specific and menstrual cycle dependent differences in circulating microparticles. Platelets. 2007;18:515–21. [PubMed]
3. Wong JH, Dukes J, Levy RE, Sos B, Mason SE, Fong TS, Weiss EJ. Sex differences in thrombosis in mice are mediated by sex-specific growth hormone secretion patterns. J Clin Invest. 2008;118:2969–78. [PMC free article] [PubMed]
4. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801–11. [PubMed]
5. Kaptoge S, White IR, Thompson SG, Wood AM, Lewington S, Lowe GD, Danesh J. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol. 2007;166:867–79. [PubMed]
6. Peters LL, Cheever EM, Ellis HR, Magnani PA, Svenson KL, Von SR, Bogue MA. Large-scale, high-throughput screening for coagulation and hematologic phenotypes in mice. Physiol Genomics. 2002;11:185–93. [PubMed]
7. Emms H, Lewis GP. Sex and hormonal influences on platelet sensitivity and coagulation in the rat. Br J Pharmacol. 1985;86:557–63. [PMC free article] [PubMed]
8. Ajayi AA, Hercule H, Cory J, Hayes BE, Oyekan AO. Gender difference in vascular and platelet reactivity to thromboxane A(2)-mimetic U46619 and to endothelial dependent vasodilation in Zucker fatty (hypertensive, hyperinsulinemic) diabetic rats. Diabetes Res Clin Pract. 2003;59:11–24. [PubMed]
9. Uzunova A, Ramey E, Ramwell PW. Effect of testosterone, sex and age on experimentally induced arterial thrombosis. Nature. 1976;261:712–3. [PubMed]
10. Johnson M, Ramey E, Ramwell PW. Androgen-mediated sensitivity in platelet aggregation. Am J Physiol. 1977;232:H381–H385. [PubMed]
11. Leng XH, Hong SY, Larrucea S, Zhang W, Li TT, Lopez JA, Bray PF. Platelets of female mice are intrinsically more sensitive to agonists than are platelets of males. Arterioscler Thromb Vasc Biol. 2004;24:376–81. [PubMed]
12. Leng XH, Zhang W, Nieswandt B, Bray PF. Effects of estrogen replacement therapies on mouse platelet function and glycoprotein VI levels. Circ Res. 2005;97:415–7. [PubMed]
13. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, Moy TF, Becker LC, Faraday N. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA. 2006;295:1420–7. [PubMed]
14. Faraday N, Goldschmidt-Clermont PJ, Bray PF. Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost. 1997;77:748–54. [PubMed]
15. Haque SF, Matsubayashi H, Izumi S, Sugi T, Arai T, Kondo A, Makino T. Sex difference in platelet aggregation detected by new aggregometry using light scattering. Endocr J. 2001;48:33–41. [PubMed]
16. Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature. 1975;253:355–7. [PubMed]
17. Jayachandran M, Miller VM. Human platelets contain estrogen receptor alpha, caveolin-1 and estrogen receptor associated proteins. Platelets. 2003;14:75–81. [PubMed]
18. Boudoulas KD, Cooke GE, Roos CM, Bray PF, Goldschmidt-Clermont PJ. The PlA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation. Arch Pathol Lab Med. 2001;125:112–5. [PubMed]
19. Miller ME, Dores GM, Thorpe SL, Akerley WL. Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions. Thromb Res. 1994;74:577–94. [PubMed]
20. Roell A, Schueller P, Schultz A, Losel R, Wehling M, Christ M, Feuring M. Effect of oral contraceptives and ovarian cycle on platelet function. Platelets. 2007;18:165–70. [PubMed]
21. Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, FitzGerald GA. COX-2-derived prostacyclin confers atheroprotection on female mice. Science. 2004;306:1954–7. [PubMed]
22. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230–5. [PubMed]
23. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961–5. [PubMed]
24. Qayyum R, Becker DM, Yanek LR, Moy TF, Becker LC, Faraday N, Vaidya D. Platelet inhibition by aspirin 81 and 325 mg/day in men versus women without clinically apparent cardiovascular disease. Am J Cardiol. 2008;101:1359–63. [PMC free article] [PubMed]
25. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988;2:349–60. [PubMed]
26. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997;349:1569–81. [PubMed]
27. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997;349:1641–9. [PubMed]
28. BMJ. Vol. 324. 2002. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients; pp. 71–86. 12. [PMC free article] [PubMed]
29. Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA. 1991;266:521–7. [PubMed]
30. Chan AT, Manson JE, Feskanich D, Stampfer MJ, Colditz GA, Fuchs CS. Long-term aspirin use and mortality in women. Arch Intern Med. 2007;167:562–72. [PubMed]
31. Kjeldsen SE, Kolloch RE, Leonetti G, Mallion JM, Zanchetti A, Elmfeldt D, Warnold I, Hansson L. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment. J Hypertens. 2000;18:629–42. [PubMed]
32. de GG. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001;357:89–95. [PubMed]
33. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306–13. [PubMed]
34. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293–304. [PubMed]
35. Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J. 2005;26:1585–95. [PubMed]
36. Steinhubl SR, Berger PB, Mann JT, III, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411–20. [PubMed]
37. Boersma E, Harrington RA, Moliterno DJ, White H, Theroux P, Van de WF, de TA, Armstrong PW, Wallentin LC, Wilcox RG, Simes J, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189–98. [PubMed]
38. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983;72:325–38. [PMC free article] [PubMed]
39. Tardiff BE, Jennings LK, Harrington RA, Gretler D, Potthoff RF, Vorchheimer DA, Eisenberg PR, Lincoff AM, Labinaz M, Joseph DM, McDougal MF, Kleiman NS. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT. Circulation. 2001;104:399–405. [PubMed]
40. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–8. [PubMed]
41. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, Go AS. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005;112:1687–91. [PMC free article] [PubMed]
42. Friberg J, Scharling H, Gadsboll N, Truelsen T, Jensen GB. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study) Am J Cardiol. 2004;94:889–94. [PubMed]
43. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70. [PubMed]
44. Gomberg-Maitland M, Wenger NK, Feyzi J, Lengyel M, Volgman AS, Petersen P, Frison L, Halperin JL. Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. Eur Heart J. 2006;27:1947–53. [PubMed]
45. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke. 1999;30:1223–9. [PubMed]
46. Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, Nasco E, Sherman DG, Talbert RL, Marler JR. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med. 2003;138:831–8. [PubMed]
47. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. (8th) 2008 June;133(6 Suppl):199S–233S. [PubMed]
48. Roquer J, Campello AR, Gomis M. Sex differences in first-ever acute stroke. Stroke. 2003;34:1581–5. [PubMed]
49. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67. [PubMed]
50. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–57. [PubMed]
51. DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, Rosenfeld LE, Mitrani G, Nemeth M. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005;149:650–6. [PubMed]
52. White RH. The epidemiology of venous thromboembolism. Circulation. 2003 June 17;107(23 Suppl 1):I4–I8. [PubMed]
53. Anderson FA, Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151:933–8. [PubMed]
54. Ageno W, Squizzato A, Garcia D, Imberti D. Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost. 2006;32:651–8. [PubMed]
55. Martinelli I. Thromboembolism in women. Semin Thromb Hemost. 2006;32:709–15. [PubMed]
56. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002;288:872–81. [PubMed]
57. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000;132:689–96. [PubMed]
58. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–33. [PubMed]
59. Cushman M, Glynn RJ, Goldhaber SZ, Moll S, Bauer KA, Deitcher S, Shrivastava S, Ridker PM. Hormonal factors and risk of recurrent venous thrombosis: the prevention of recurrent venous thromboembolism trial. J Thromb Haemost. 2006;4:2199–203. [PubMed]
60. Keenan CR, White RH. The effects of race/ethnicity and sex on the risk of venous thromboembolism. Curr Opin Pulm Med. 2007;13:377–83. [PubMed]
61. White RH, Zhou H, Murin S, Harvey D. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost. 2005;93:298–305. [PubMed]
62. White RH, Dager WE, Zhou H, Murin S. Racial and gender differences in the incidence of recurrent venous thromboembolism. Thromb Haemost. 2006;96:267–73. [PubMed]
63. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med. 2004;350:2558–63. [PubMed]
64. Baglin T, Luddington R, Brown K, Baglin C. High risk of recurrent venous thromboembolism in men. J Thromb Haemost. 2004;2:2152–5. [PubMed]